Year: 2023

FORT WORTH, Texas, Dec. 11, 2023 (GLOBE NEWSWIRE) — American Airlines has been named to the Dow Jones Sustainability World Index (DJSI World) for the first time, one of only two passenger airlines included in the Index. American also returns to the Dow Jones Sustainability North America Index (DJSI North America) for the third year in a row. The Dow Jones Sustainability World Index comprises global sustainability leaders as identified by S&P Global through the Corporate Sustainability Assessment. It represents the top 10% of the largest 2,500 companies in the S&P Global Broad Market Index based on long-term economic, environmental and social criteria. “Inclusion on the DJSI World Index recognizes our work to improve the reliability of our operation, invest in our team members and operate more sustainably,” said American’s...

Novaturas Group, the leader in the Baltic tourism market, which also includes Estonian Novatours, signed a cooperation agreement with Heston Airlines, an airline focused on charter and ACMI* flights. From the start of the next summer season, Heston will become Novatours’ main flight partner in Estonia. This strategic partnership aims to offer an excellent travel experience, enhancing the overall quality and reliability of services provided by both entities. “We are honored to announce the partnership with Heston Airlines which marks a significant company’s milestone, particularly benefiting Estonian travelers. This newly signed agreement is based on focus to enrich the customer experience. Heston Airlines’ business model and objectives, as well as its modern fleet, attention to sustainability fit with our attitude, values...

LONGUEUIL, Québec, Dec. 11, 2023 (GLOBE NEWSWIRE) — Reunion Gold Corporation (TSXV: RGD; OTCQX: RGDFF) (the “Company” or “Reunion Gold”) wishes to comment on the border controversy between the Co-operative Republic of Guyana and the Bolivarian Republic of Venezuela following a consultative referendum held last week in Venezuela. The internationally recognized border between Guyana and Venezuela was established on October 3, 1899 by an arbitration panel (Arbitral Award of 3 October 1899). In 1962, Venezuela claimed that the decision was invalid. Guyana has brought this matter before the International Court of Justice in 2018 asking the Court to confirm the 1899 Arbitral Award. The recent escalation of Venezuela claims over what is referred to as the Essequibo region is widely attributed to recent oil discoveries by ExxonMobil and...

MONTREAL, Dec. 11, 2023 (GLOBE NEWSWIRE) — Sirios Resources Inc. (TSX-V: SOI; OTCQB: SIREF) announces that its Annual Meeting of Shareholders will be held on Monday December 18, 2023 at 10 a.m. (Eastern Standard Time) both in person at 1400 Marie-Victorin, Suite 210, Saint-Bruno-de-Montarville (Quebec) and via live webinar. Shareholders of the company are invited to register in advance for the webinar at the following address: http://us06web.zoom.us/webinar/register/WN_UWKuDjnGSBytMISm3j5Rzg The proceedings of the meeting will be in French and will be followed by a presentation from the President in English. A question period will then take place in both languages. The meeting will be an opportunity to take stock of the positive developments of the past year and to highlight future opportunities for the company. We look forward...

Innofactor Plc Announcement 11.12.2023          Innofactor Plc: Share Repurchase 11.12.2023       In the Helsinki Stock Exchange         Trade date 11.12.2023  Bourse trade Buy  Share IFA1V  Amount 4,300 SharesAverage price/ share 1.1599 EURTotal cost 4,987.57 EUR          Innofactor Plc now holds a total of 584 329 sharesincluding the shares repurchased on 11.12.2023          On behalf of Innofactor Plc         Nordea Bank Oyj         Janne Sarvikivi Sami Huttunen       Additional information:    Sami Ensio, CEO    Innofactor Plc    Tel. +358 50 584 2029    sami.ensio@innofactor.com         www.innofactor.com       AttachmentInnofactor_11.12_trades

Positive preliminary efficacy data with a favorable safety profile support plans to develop NX-5948 broadly in chronic lymphocytic leukemia (CLL) Rapid durable complete responses in a heavily pretreated relapsed/refractory patient population support continued development of NX-2127 in non-Hodgkin lymphoma (NHL) Nurix will webcast a Key Opinion Leader (KOL) event at 8:30 p.m. PT today to review data presented at the ASH meeting from its BTK degrader portfolio SAN FRANCISCO, Dec. 11, 2023 (GLOBE NEWSWIRE) — Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical stage biopharmaceutical company developing targeted protein modulation drugs designed to treat patients with hematologic malignancies and solid tumors, today presented positive clinical data from its orally available degraders of BTK, NX-5948 and NX-2127, which are being evaluated...

Preliminary evidence of clinical antimyeloma activity, including reduction in paraprotein, demonstrated in multiple patients Clean safety profile with only Grade 1 and 2 treatment related adverse events and no dose limiting toxicities or dose reductions Clinical activity, safety profile, and dose-dependent increases in immune cell activation support potential for combination studies with other multiple myeloma agents, including BCMA- and CD38-directed therapies Company to pursue strategic partnership for combination studies, resulting in extension of cash runway into 2026 Company to host conference call and webcast today at 4:30 pm ET SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, Dec. 11, 2023 (GLOBE NEWSWIRE) — ORIC Pharmaceuticals, Inc. (Nasdaq: ORIC), a clinical stage oncology company focused on developing treatments that address...

Substantial, dose-dependent reductions in serum hepcidin and increases in serum iron Hematologic response demonstrated by increased hemoglobin levels and reduction in transfusion burden DISC-0974 was generally well-tolerated at all evaluated dosesWATERTOWN, Mass., Dec. 11, 2023 (GLOBE NEWSWIRE) — Disc Medicine, Inc. (NASDAQ:IRON), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases, today announced data from initial dose cohorts of its ongoing phase 1b/2 study of DISC-0974, a monoclonal antibody designed to suppress hepcidin by inhibiting the hemojuvelin (HJV) co-receptor, in MF patients with anemia. The initial data demonstrated that treatment with DISC-0974 substantially decreased serum hepcidin,...